{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-000621","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.567965+00:00","generated_at":"2026-06-07T03:05:31.765526+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M","bullets":["Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).","FY 2023 revenue estimated $18.1-18.3M, up from $12.9M in FY 2022 (40-42% YoY increase).","Cash at Dec 31, 2023 estimated $8.6M vs $20.5M a year ago; Q4 cash burn improved to $1.7M from $3.6M.","CEO cited strong demand for EksoNR and Indego; final results expected in March 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-000621","json":"https://secwatch.observer/filing/0001437749-24-000621.json","markdown":"https://secwatch.observer/filing/0001437749-24-000621.md","text":"https://secwatch.observer/filing/0001437749-24-000621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/ekso20240104_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:05:31.765526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"27f1041915514d519518be5b580b6f2249b13ad2","claim":"EKSO BIONICS HOLDINGS, INC. reported the fiscal year ended December 31, 2023 results: revenue in the range of $18.1 million to $18.3 million.","evidence_excerpt":"Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"in the range of $18.1 million to $18.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"bb22e7478441beb5e6c8d09a3fc990bab06c2d54","claim":"EKSO BIONICS HOLDINGS, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue in the range of $4.7 million to $4.9 million.","evidence_excerpt":"Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"in the range of $4.7 million to $4.9 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}